ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
US Tech 100
19,884.80
0.46%
Dow Jones
40,211.72
0.53%
Brent Oil
83.945
-0.47%
Bitcoin
63,641.07
-1.87%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Merus NV (MRUS) Quote

Merus NV

Merus NV (MRUS)

NASDAQ
58.10
0.84
(1.47%)
Closed July 16 4:00PM
Delayed by 15 minutes
58.10
0.01
(0.02%)
After Hours: 6:27PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
58.10
Bid
45.00
Ask
58.50
Volume
594,266
57.09 Day's Range 58.31
19.805 52 Week Range 61.61
Market Cap
3.36B
Previous Close
57.26
Open
57.57
Last Trade
5
@
58.49
Last Trade Time
Financial Volume
$ 34,209,726
VWAP
57.5664
Average Volume (3m)
1,104,207
Shares Outstanding
58,687,551
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
www.merus.nl
Headquarters
Utrecht, Utrecht, Nld
Founded
1970
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $57.26. Over the last year, Merus NV shares have traded in a share price range of $ 19.805 to $ 61.61.

Merus NV currently has 58,687,551 shares outstanding. The market capitalization of Merus NV is $3.36 billion.

MRUS Latest News

More News

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

July 08 2024
GlobeNewswire Inc.

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

July 01 2024
GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities

June 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 12 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

June 03 2024
GlobeNewswire Inc.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

June 02 2024
GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 30 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
14.017.4135699759754.0958.3153.8895606156.41340768CS
41.512.6683159568856.5961.2850.5189001756.21943206CS
1218.0545.068664169840.0561.6139.93110420752.64219604CS
2625.6979.265658747332.4161.6131.2781339248.97901163CS
5230.64111.58048069927.4661.6119.80559105441.19784567CS
15640.44228.9920724817.6661.6112.0341010031.4668791CS
26042.79279.49052906615.3161.6110.1829351829.21232165CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
SHOTWSafety Shot Inc
$ 0.41
(115.79%)
7.56k
DATSDatChat Inc
$ 1.89
(81.73%)
54.75M
CYNCYNGN Inc
$ 9.18
(53.77%)
17.79M
SCNIScinai Immunotherapeutics Ltd
$ 5.80
(42.86%)
29.37M
ASLNASLAN Pharmaceuticals Ltd
$ 1.36
(-46.67%)
1.16M
KZIAKazia Therapeutics Ltd
$ 0.5593
(-37.56%)
15.34M
LCFYLocafy Ltd
$ 3.5597
(-36.32%)
584.38k
NAASNaaS Technology Inc
$ 2.82
(-33.02%)
1.94M
ZENVZenvia Inc
$ 1.67
(-26.75%)
658.26k
FFIEFaraday Future Intelligent Electric Inc
$ 0.5152
(22.09%)
217.92M
NVDANVIDIA Corporation
$ 128.44
(-0.62%)
208.32M
SQQQProShares UltraPro Short QQQ
$ 7.46
(-0.67%)
155.14M
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
TSLATesla Inc
$ 252.64
(1.78%)
147.31M

MRUS Discussion

View Posts
Phosphene Phosphene 4 years ago
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
👍️0
Phosphene Phosphene 4 years ago
The Baker Brothers have 7% ownership.

https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
👍️0
Phosphene Phosphene 4 years ago
Board Member: Victor Sandor

https://ir.merus.nl/board-member/victor-sandor

https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
👍️0
Phosphene Phosphene 4 years ago
Second Quarter 2020 Results:

https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
👍️0
Phosphene Phosphene 4 years ago
https://merus.nl/
👍️0
Phosphene Phosphene 4 years ago
European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
👍️0

Your Recent History

NASDAQ
MRUS
Merus NV
NASDAQ
TIGO
Millicom International C...
USOTC
WKCMF
Wacker Chemie Ag Muenchen (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved